PNA Medical Corner: Clinical Outcomes and Self-Reported Symptoms in Patients with Acromegaly

AnnKlibanski2015 CroppedPNA Medical Corner: This month the PNA Medical Corner showcases an article co-written by PNA member Dr. Anne Klibanski, Director of the Neuroendocrine and Pituitary Tumor Clinical Center at Massachusetts General Hospital The study is called Clinical Outcomes and Self-Reported Symptoms in Patients with Acromegaly: Eight-Year Follow-Up of a Lanreotide Study. It found that lanreotide is well-tolerated in the long term and does reduce symptoms.

Khairi S1, Sagvand BT1, Pulaski-Liebert KJ1, Tritos NA1, Klibanski A1, Nachtigall LB1.
1From: Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.

Abstract

OBJECTIVES:

The aim of this study was to evaluate the proportion of patients with acromegaly who remained on long-term lanreotide depot after completion of an open label multicenter phase III clinical trial (SALSA), compare symptom score at long-term follow-up with baseline and correlate these with individual longitudinal clinical outcomes.

METHODS:

Records of all subjects previously enrolled at the Massachusetts General Hospital site of SALSA were reviewed. Those who remained on lanreotide were interviewed and asked to complete a questionnaire that they had completed in SALSA in 2007 regarding their current symptomatology and injection side effects as well as to complete the Acromegaly Quality of life questionnaire. Furthermore, clinical, biochemical and radiographic data related to acromegaly and its co-morbidities were tracked throughout the course of follow-up.

RESULTS:

Six out of seven patients chose to remain on lanreotide and five of them continued lanreotide depot through last follow up, for up to 8 years or in one case until death. In all cases, lanreotide remained well tolerated and IGF-1 levels and pituitary imaging remained well controlled on stable doses. While co-morbidities persisted or developed, self-reported symptom score after up to 8 years of therapy showed a significant decrease in frequency or resolution in symptoms that were reported at baseline.

CONCLUSION:

This study shows a significant decrease in frequency or resolution in self-reported symptoms in well-controlled patients receiving long-term lanreotide therapy.

Khairi S, Sagvand BT, Pulaski-Liebert KJ, Tritos NA, Klibanski A, Nachtigall LB.
Endocr Pract. 2016 Sep 28. [Epub ahead of print]

Print

Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now